« Back
Home /
Sorafenib

Sorafenib

Item no.	HY-10201-1g
Manufacturer	MedChem Express
CASRN	284461-73-0
Amount	1 g
Quantity options	100 mg 10 mM/1 mL 1 g 500 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109.\|[2]El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16.\|[3]Jin W, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017 Jan;37(1):273-280.\|[4]Li M, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017 Aug 29. ACS Appl Mater Interfaces. 2017 Apr 12;9(14):12195-12202.\|ACS Chem Biol. 2016 Apr 15;11(4):992-1000.\|ACS Chem Biol. 2017 Jan 20;12(1):282-290. \|ACS Nano. 2023 Nov 15.\|Acta Pharm Sin B. 2023 Mar 31.\|Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.\|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Adv Healthc Mater. 2023 Apr 14;e2203120.\|Adv Sci (Weinh). 2021 Jan 29;8(6):2002831.\|Adv Sci (Weinh). 2022 May;9(15):e2105894.\|Adv Sci (Weinh). 2023 Jul 23;e2302640.\|Adv Sci (Weinh). 2023 Jun 17;e2206798.\|Adv Sci (Weinh). 2024 Jul 9:e2402327.\|Advances in Parkinsons Disease. 2021, 10, 1-13.\|Am J Dig Dis (Madison). 2015;2(2):95-99.\|Am J Hypertens. 2025 Jan 16;38(2):104-110.\|Am J Transl Res. 2020;12(3):825-836.\|Am J Transl Res. 2023 Feb 28;15(2):896-913.\|Biochem Bioph Res Co. 2020 Sep 3;529(4):1086-1093.\|Biochem Biophys Res Commun. 13 January 2022.\|Biochem Biophys Res Commun. 2023 Jun 10.\|Biochem Pharmacol. 2023 Apr 18;115554.\|Biochem Pharmacol. 2023 May 15;115593.\|Biochem Pharmacol. 2019 Nov;169:113612. \|Biol Direct. 2024 Nov 11;19(1):110.\|Biology (Basel). 2023 Oct 16, 12(10), 1337.\|Biomaterials. 16 September 2022.\|Biomaterials. 17 March 2022.\|Biomed Pharmacother. 2016 Dec 6;86:27-31.\|Biomed Pharmacother. 2020 Jun;126:109862.\|Biomed Pharmacother. September 2022, 113540.\|Biomed Res Int. 2019 Nov 28;2019:2410845.\|bioRxiv. 2021 Jan 25.\|BMC Complement Med Ther. 2023 Jun 26;23(1):210.\|BMC Cancer. 2019 Aug 1;19(1):760. \|Br J Cancer. 2017 Sep 26;117(7):974-983.\|Br J Pharmacol. 2021 Feb;178(3):636-653.\|Braz J Med Biol Res. 2021 May 31;54(9):e10390.\|Can J Gastroenterol Hepatol. 2022.\|Cancer Cell Int. 2019 Aug 27;19:222.\|Cancer Discov. 2019 Dec;9(12):1686-1695.\|Cancer Discov. 2021 Oct;11(10):2544-2563.\|Cancer Lett. 20 October 2021.\|Cancer Lett. 2019 May 28;450:132-143.\|Cancer Lett. 2021 Jul 30;S0304-3835(21)00382-7.\|Cancers (Basel). 2023 Nov 3, 15(21), 5280.\|Cancers. 2020 Jun 30;12(7):1737.\|Cell Biol Toxicol. 2023 Mar 31.\|Cell Biol Toxicol. 2024 Nov 26;40(1):104.\|Cell Commun Signal. 2024 Aug 7;22(1):391.\|Cell Death Differ. 2021 Apr;28(4):1222-1236.\|Cell Death Dis. 2021 Jul 9;12(7):691.\|Cell Death Dis. 2022 Feb 4;13(2):118.\|Cell Death Dis. 2023 Jan 12;14(1):22.\|Cell Death Dis. 2024 Jan 18;15(1):66.\|Cell Death Dis. 2024 Jun 5;15(6):395.\|Cell Death Dis. 2025 Jan 26;16(1):42.\|Cell Death Dis. 2019 Apr 15;10(5):331.\|Cell Death Discov. 2022 Aug 17;8(1):365.\|Cell Death Discov. 2023 Sep 30;9(1):362.\|Cell Discov. 2022 May 3;8(1):40.\|Cell Metab. 2021 Sep 8;S1550-4131(21)00375-2.\|Cell Mol Gastroenterol Hepatol. 2024 Dec 30:101454.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Cell Rep. 2023 Dec 12;42(12):113563.\|Cell Rep. 2024 Nov 27;43(12):114996.\|Cell Rep. 2024 Oct 24;43(11):114885.\|Cell Signal. 2024 Jun 27:111278.\|Chem Cent J. 2017 Jan 3;11:1.\|Chemical Engineering and Applied Chemistry Institute of Biomaterials and Biomedical Engineering, University of Toronto. 2019 Aug.\|Chemosphere. 2022 Sep 7;136354.\|Chin J Nat Med. 2022 Mar;20(3):202-209.\|Chin Med. 2024 Aug 24;19(1):113.\|Clin Cancer Res. 2024 Jul 25.\|Clin Med Insights Oncol. 2024 Oct 16:18:11795549241285387.\|Clin Sci. 2021 Jul 20;CS20210571.\|Clin Sci. 2024 Sep 18;138(18):1131-1150.\|Clin Transl Med. 2023 Jun;13(6):e1300.\|Commun Biol. 2024 Oct 8;7(1):1279.\|Commun Biol. 2025 Feb 8;8(1):205.\|Comput Biol Med. 2024 Feb, 169, 107975.\|Dig Liver Dis. 2023 May 23;S1590-8658(23)00618-7.\|Discov Oncol. 2023 May 27;14(1):83.\|Diseases. 2023 Oct 23;11(4):147.\|Drug Deliv. 2023 Dec;30(1):2174209.\|Drug Des Devel Ther. 2024 Sep 12:18:4065-4088.\|Endocr J. 2017 Nov 29;64(11):1115-1123.\|Endocrinology. 2023 Sep 13;bqad135.\|Environ Toxicol. 2021 Oct 18.\|Eur J Med Chem. 2024 Mar 5:267:116209.\|Eur J Pharmacol. 2021 Jun 1;174217.\|Evid Based Complement Alternat Med. 15 Oct 2022.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Exp Cell Res. 2021 Jul 29;112755.\|Exp Cell Res. 2022 May 25;113223.\|Exp Hematol Oncol. 2016 Jul 29;5:22. \|Free Radic Biol Med. 2020 Nov 20;160:303-318.\|Free Radic Biol Med. 2021 Feb 1;163:141-152.\|Front Biosci (Landmark Ed). 2024 Jan 19, 29(1), 3.\|Front Oncol. 2021 Jul 13;11:704042.\|Front Oncol. 2022 Jul 8;12:939605.\|Front Pharmacol. 2022 Jul 11;13:930958.\|Front Pharmacol. 2024 Apr 5.\|Genes Dis. 2023 Sep 16, 101114.\|Gut Microbes. 2024 Jan-Dec;16(1):2410474.\|Heliyon. 2024 Jan 13, e24461.\|Heliyon. 2024 May 31.\|Hepatol Commun. 2024 Mar 29;8(4):e0405.\|Immunology. 2023 Apr 17.\|Int Immunopharmacol. 2024 Sep 30;143(Pt 1):113226.\|Int J Biol Sci. 2018 Apr 25;14(5):577-585.\|Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.\|Int J Clin Exp Pathol. 2017;10(3):3033-3042.\|Int J Med Sci. 2021 Jan 29;18(6):1456-1464.\|Int J Mol Sci. 2023 Dec 23, 25(1), 269.\|Int J Nanomedicine. 2024 Dec 3:19:12975-12998.\|Integr Biol (Camb). 2018 Oct 15;10(10):646-657.\|iScience. 2023 May 29, 106994.\|J Cancer. 2021 Jan 1;12(2):343-357.\|J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:220-224.\|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.\|J Clin Transl Hepatol. 2025 Jan 28;13(1):15-24.\|J Ethnopharmacol. 2021 Aug 4;280:114480.\|J Exp Clin Cancer Res. 2022 Mar 30;41(1):116.\|J Exp Clin Cancer Res. 2023 Jan 6;42(1):6.\|J Exp Clin Cancer Res. 2018 Nov 29;37(1):295.\|J Extracell Vesicles. 2024 Jul;13(7):e12468.\|J Hepatocell Carcinoma. 2023 Apr 11;10:611-629.\|J Immunother Cancer. 2022 Aug;10(8):e004006.\|J Med Chem. 2019 Nov 14;62(21):9593-9599. \|J Mol Med (Berl). 2022 Feb 5.\|J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. \|J Transl Med. 2022 Jun 6;20(1):255.\|J Transl Med. 2023 Jan 9;21(1):9.\|J Transl Med. 2024 Aug 28;22(1):792.\|J Transl Med. 2025 Feb 28;23(1):244.\|Journal of Pharmaceutical Research International. 33(47B): 274-279, 2021.\|Kaohsiung J Med Sci. 16 November 2021.\|Lab Chip. 2018 Nov 6;18(22):3379-3392.\|Med Oncol. 2022 Sep 29;39(12):221.\|Mol Cancer Ther. 2020 May;19(5):1197-1209.\|Mol Carcinog. 2023 May 22.\|Mol Cell Probes. 2022 Nov 25;101877.\|Mol Cell. 2023 Dec 7;83(23):4334-4351.e7.\|Mol Oncol. 19 August 2022.\|Molecules. 2018 Mar 23;23(4). pii: E736.\|Nat Cancer. 2024 May 30.\|Nat Commun. 2022 Mar 18;13(1):1478.\|Nat Commun. 2024 Sep 10;15(1):7923.\|Nat Commun. 2025 Jan 2;16(1):87.\|Neuropharmacology. 2019 Jan 30;148:347-357.\|Oncogene. 2021 Jul 10.\|Oncogene. 2022 Feb 10.\|Oncol Rep. 2017 Jan;37(1):273-280. \|Oncol Rep. 2018 Sep;40(3):1525-1532. \|Oncol Rep. 2020 Dec 9.\|Oncotarget. 2017 May 2;8(18):29771-29784.\|Pak J Zool. 2021 May.\|Patent. US20180263995A1.\|Patent. US20220305013A1.\|Personalized Medicine Universe. 2019 May. \|Pharmacol Res. 2021 Dec 29;106050.\|Pharmacol Res. 2022 Jun;180:106244.\|Phytochemistry. 2021 Jun 1;189:112816.\|Phytomedicine. 2023 Nov 25, 155225.\|Phytomedicine. 8 September 2021, 153740.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Prostate. 2018 Apr;78(5):343-352.\|Redox Biol. 2022: 102564.\|Redox Biol. 2024 Mar 28:72:103131.\|Redox Biol. 2024 Nov 5:78:103419.\|Res Sq. 2024 Sep 16.\|Research Square Preprint. 2021 Aug.\|Research Square Preprint. 2022 Jan.\|Research Square Preprint. 2022 Jul.\|Research Square Preprint. 2022 May.\|Research Square Preprint. 2023 Mar 29.\|Research Square Preprint. 2023 Nov 11.\|Research Square Print. 2023 Feb 20.\|Research Square Print. October 3rd, 2022.\|RSC Adv. 2018 8:6425-6435.\|Sci Rep. 2017 Sep 8;7(1):11006. \|Sci Rep. 2022 Apr 21;12(1):6120.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Sens Actuators B Chem. 2024 Nov 1.\|Signal Transduct Target Ther. 2023 Sep 14;8(1):348.\|SSRN. 2023 Apr 24.\|SSRN. 2023 Jan 27.\|SSRN. 2024 Oct 16.\|Stem Cell Res Ther. 2023 Apr 1;14(1):58.\|Theranostics. 2020 Aug 21;10(23):10498-10512. \|Toxicol In Vitro. 2021 Jul 20;76:105226.\|Toxicology. 2023 Mar 2;153475.\|Transl Oncol. 2024 Nov 27:51:102214.\|Virol Sin. 2023 Jul 3;S1995-820X(23)00079-2.\|World J Gastroenterol. 2021 Jul 28;27(28):4667-4686.\|Adv Sci (Weinh). 2022 Nov 29;e2203718.\|Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. \|Am J Transl Res. 2021 Jul 15;13(7):7508-7523.\|Autophagy. 2021 May 7;1-13.\|Bone Res. 2024 Apr 10;12(1):24.\|Fundam Clin Pharmacol. 2020 Oct 4. \|Int J Biochem Cell Biol. 2020 Sep;126:105820.\|Int J Mol Sci. 2022, 23(19), 11092.\|J Enzyme Inhib Med Chem. 2020 Dec;35(1):344-353.\|Math Biosci Eng. 2019 Jul 8;16(6):6319-6334.\|NPJ Syst Biol Appl. 2019 Aug 16;5:29.\|Oncotarget. 2017 Oct 6;8(52):90185-90196. \|PLoS Genet. 2025 Mar 17;21(3):e1011614.\|PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. \|Saudi Pharm J. 2023 Jun 1.
Smiles	O=C(NC(C=C1)=CC=C1OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Bay 43-9006
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	464.83
Product Description	Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 45 mg/mL
Manufacturer - Pathway	Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Isoform	B-Raf; C-Raf; PDGFRβ; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10201-1g-safety-datasheet.pdf